MSD upgrades after Q3 sales fared better than expected

A 14% revenue increase has meant MSD can set its sights a little higher for the full year.

by marketwire, translated by daniel pedersen

MSD’s revenues have gone up 14% in the third quarter, totaling USD 14.96bn. That’s well over the analyst consensus estimate of USD 14.11bn.

The better-than-expected sales development has been, in part, driven by cancer treatment Keytruda achieving a 20% boost compared to the same time last year, coming in at USD 5.43bn. Analysts’ prediction was USD 5.34bn.

HPV vaccine Gardasil has also fared better than in Q3, 2021, when sales amounted to USD 2.05bn, booking USD 2.29 in Q3, 2022.

Diabetes treatments Januvia and Janumet brought in USD 717m and USD 417m, respectively. On the first account, this tops predictions of USD 710m, but as for the second, sales did not live up to the USD 425.5m analyst expectation.

Adjusted earnings per share also surpassed the analyst forecast, with USD 1.85 per share being reported, surpassing the prognosis of USD 1.73.

MSD rounds off the financial report by raising sales expectations for the full-year to USD 58.5–59bn from the former USD 57.5–58.5bn, with the consensus estimate being USD 58.46bn. The adjusted EPS figure for 2022 is expected to land in the interval of 7.32–7.37 versus USD 7.25–7.35. The analyst prognosis was USD 7.32.

MSD diabetes drug found to contain possible carcinogen

Merck loses interest in Seagen

MSD diabetes drug found to contain possible carcinogen
For subscribers
Merck loses interest in Seagen
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Former Demant Executive Vice President Arne Boye Nielsen was found responsible for creating an "unsafe psychological work environment" in an internal legal investigation. | Foto: Demant / Pr

Hearing health

Demant Foundation continues to work with ousted Demant executive

While the findings of a legal investigation were so serious that a Demant executive was fired, the majority owner of the hearing aid company subsequently elected him to several boards.

Sacked Demant executive receives USD 2.6 million golden handshake

Demant Board has "full confidence" in management's handling of unsafe work environment

For subscribers

Hearing health

CHMP recommends ten new medicines in June

For subscribers

Foto: George Frey/Reuters/Ritzau Scanpix

Pharma & biotech

Cosmetic Ozempic use under fire in EU amid drug shortages

Regulation

CHMP recommends conditional approval for Genmab and Abbvie's epcoritamab

For subscribers

Pharma & biotech

Pharmacosmos calls off the hunt for investors

For subscribers

Pharma & biotech

Novo to limit Wegovy’s China launch to avoid global disruption

Analyst on Novo Nordisk writedown: "It is a reminder of the risks"

On Wednesday, Novo Nordisk made a write-down of DKK 5.7bn (USD 817m) after a failed study.

Novo Nordisk snaps up partner's hemophilia candidate and gene editing technology

A five-year collaboration is coming to an end as Novo Nordisk has decided to acquire a drug candidate and gene technology from its former partner.

For subscribers

Bavarian Nordic expects Jynneos to be fully effective against new mpox variant

Bavarian Nordic’s vaccine Jynneos is the only approved vaccine against the disease mpox.

Novo Nordisk implements hiring freeze in certain departments

Since 2021, Novo Nordisk has increased its number of employees by 20,000 to total 66,000.

For subscribers

Foto: Medwatch/photo by Ulrich Quistgaard

Genmab cancer drug approved in new indication in US

Epkinly has become the first and only subcutaneously administered T-cell engaging bispecific antibody approved in the US for the treatment of this patient population.

Novo Nordisk blood pressure candidate ends in USD 817m flop

Novo Nordisk acquired ocedurenone from KBP Biosciences in 2023.

Novo Nordisk implements hiring freeze in certain departments

Since 2021, Novo Nordisk has increased its number of employees by 20,000 to total 66,000.

For subscribers

Hearing health

Demant Foundation continues to work with ousted Demant executive

While the findings of a legal investigation were so serious that a Demant executive was fired, the majority owner of the hearing aid company subsequently elected him to several boards.

For subscribers

Pharma & biotech

Cosmetic Ozempic use under fire in EU amid drug shortages

The success of Novo Nordisk’s Ozempic and Wegovy as well as blockbuster shots made by rival Eli Lilly has left some patients with diabetes struggling to continue their treatment.

Pharma & biotech